Article
Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis - 1 Sept 2020
Parker Margaret M, Ticau Simina, Butler James, Erbe David, Merkel Madeline, Aldinc Emre, Hinkle Gregory, Nioi Paul
Abstract excerpt
Background: Destabilised transthyretin (TTR) can result in the progressive, fatal disease transthyretin-mediated (ATTR) amyloidosis. A stabilising TTR mutation, T119M, is the basis for a therapeutic strategy to reduce destabilised TTR. Recently, T119M was associated with extended lifespan and lower risk of cerebrovascular disease in a Danish cohort. We aimed to determine whether this finding could be replicated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.